Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cannabis Biotech Scientific Team Examining Terpene Isolation

PUGE

Puget Technologies (OTCBB:PUGE) revealed its subsidiary, Cannabis Biotech, is placing a high focus on the isolation of terpenes and their unique synergistic interaction. As part of its commitment to discovering and developing the highest quality medical marijuana products, Cannabis Biotech’s scientific team is exploring the benefits of terpenes.

In the cannabis plant, terpenes are responsible for delivering the complex effects of the whole plant’s medicinal benefits and play a role in its aroma and flavor. Terpenes are believed to interact synergistically with cannabinoids to improve the efficacy of medical marijuana. Cannabinoids are a group of compounds present in marijuana and occur naturally in the nervous and immune systems of humans and animals.

Kenneth Morrow, prominent international marijuana authority and terpene research pioneer, is heading up Cannabis Biotech’s scientific team. He said, “We look forward to investigating terpenes and discovering what benefits they hold.” He added, “Terpene isolation could play a major role in the development of the medical marijuana industry by improving its effectiveness.”

Additional information about Cannabis Biotech can be found at http://www.cannabisbiotech.com.

About Puget Technologies (PUGE)

Puget Technologies is a publicly traded company on the OTCBB Market stock exchange. Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Product lines under development include B-29 Energy Drinks and several medical marijuana products through its subsidiary, Cannabis Biotech. Much of Puget’s resources are dedicated to research and development to provide consumers with quality options while meeting investor expectations.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today